Ergomed (AIM:ERGO) - Prezzo delle azioni, notizie e analisi

La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

ERGO Panoramica delle azioni

Ergomed plc, together with its subsidiaries, provides clinical trial planning, management, and monitoring; and drug safety and medical information services in the United Kingdom, rest of Europe, the Middle East, Africa, North America, and internationally.

Informazioni sull'azienda

ERGO analisi fondamentale
Punteggio fiocco di neve
Valutazione	0/6
Crescita futura	3/6
Prestazioni passate	3/6
Salute finanziaria	6/6
Dividendi	0/6

Premi

Si prevede che gli utili cresceranno del 14.17% all'anno

Gli utili sono cresciuti del 12.3% nell'ultimo anno

Analisi del rischio

Prezzo delle azioni volatile negli ultimi 3 mesi

Gli azionisti sono stati diluiti nell'ultimo anno

Ergomed plc Concorrenti

hVIVO

AIM:HVO

UK£202.4m

C4X Discovery Holdings

AIM:C4XD

UK£30.3m

Genus

LSE:GNS

UK£1.1b

Bioventix

AIM:BVXP

UK£229.7m

Storia dei prezzi e prestazioni

Riepilogo dei massimi storici, delle variazioni e dei cali di prezzo di tutti i tempi per Ergomed
Prezzi storici delle azioni
Prezzo attuale dell'azione	UK£13.46
Massimo di 52 settimane	UK£13.80
Minimo di 52 settimane	UK£8.95
Beta	0.79
1Variazione di 1 mese	0.90%
Variazione a 3 mesi	21.26%
Variazione di 1 anno	3.54%
3Variazione a 3 anni	67.41%
Variazione a 5 anni	812.54%
Variazione dall'IPO	728.31%

Notizie e aggiornamenti recenti

Recent updates

If You Had Bought Ergomed (LON:ERGO) Stock Five Years Ago, You Could Pocket A 643% Gain Today

Feb 22

Has Ergomed plc's (LON:ERGO) Impressive Stock Performance Got Anything to Do With Its Fundamentals?

Jan 18

Ergomed plc's (LON:ERGO) Intrinsic Value Is Potentially 20% Below Its Share Price

Dec 13

We Think Ergomed's (LON:ERGO) Statutory Profit Might Understate Its Earnings Potential

Nov 23

Rendimenti per gli azionisti

	ERGO	GB Life Sciences	GB Mercato
7D	0.1%	1.2%	0.5%
1Y	3.5%	-36.7%	11.8%

Ritorno vs Industria: ERGO ha superato il UK Life Sciences che ha restituito -33.9 % nell'ultimo anno.

Rendimento vs Mercato: ERGO ha superato il mercato UK che ha restituito 13.1 % nell'ultimo anno.

Volatilità dei prezzi

Is ERGO's price volatile compared to industry and market?
ERGO volatility
ERGO Average Weekly Movement	8.1%
Life Sciences Industry Average Movement	7.4%
Market Average Movement	4.7%
10% most volatile stocks in GB Market	9.6%
10% least volatile stocks in GB Market	2.7%

Prezzo delle azioni stabile: Il prezzo delle azioni di ERGO è stato volatile negli ultimi 3 mesi.

Volatilità nel tempo: La volatilità settimanale ( 8% ) di ERGO è rimasta stabile nell'ultimo anno, ma è comunque superiore al 75% delle azioni UK.

Informazioni sull'azienda

Fondato	I dipendenti	AMMINISTRATORE DELEGATO	Sito web
1997	1,400	n/a	www.ergomedplc.com

Ergomed plc Riepilogo dei fondamenti

Come si confrontano gli utili e i ricavi di Ergomed con la sua capitalizzazione di mercato?
ERGO statistiche fondamentali
Capitalizzazione di mercato	UK£701.05m
Guadagni(TTM)	UK£15.00m
Ricavi(TTM)	UK£152.09m

46.7x

Rapporto P/E

4.6x

Rapporto P/S

ERGO è sopravvalutato?

Vedi Fair Value e analisi di valutazione

Guadagni e ricavi

Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM)
ERGO Conto economico (TTM)
Ricavi	UK£152.09m
Costo del fatturato	UK£68.82m
Profitto lordo	UK£83.27m
Altre spese	UK£68.27m
Guadagni	UK£15.00m

Ultimi guadagni dichiarati

Jun 30, 2023

Prossima data di guadagno

n/a

Utile per azione (EPS)	0.29
Margine lordo	54.75%
Margine di profitto netto	9.86%
Rapporto debito/patrimonio netto	0%

Come si è comportato ERGO nel lungo periodo?

Vedi performance storica e confronto

ERGO Panoramica delle azioni

Premi

Analisi del rischio

Ergomed plc Concorrenti

AIM:HVO

UK£202.4m

AIM:C4XD

UK£30.3m

LSE:GNS

UK£1.1b

AIM:BVXP

UK£229.7m

Storia dei prezzi e prestazioni

Notizie e aggiornamenti recenti

Ergomed Submits an Application London Stock Exchange in Relation to the Cancellation of the Admission to Trading of its Shares on AIM, Expects to Take Place on 14 November 2023

Permira Advisers Ltd. completed the acquisition of Ergomed plc (AIM:ERGO) from Amati Global Investors Ltd. and others.

Ergomed Confirms Expected Scheme Timetable

Ergomed plc (AIM:ERGO) acquired Panacea Pharma Projects Limited from Stuart Colligon.

Permira Advisers Ltd. entered into a scheme of arrangement to acquire Ergomed plc (AIM:ERGO) from Amati Global Investors Ltd. and others for approximately £700 million.

Ergomed plc to Report Q2, 2023 Results on Sep 26, 2023

Recent updates

Ergomed Submits an Application London Stock Exchange in Relation to the Cancellation of the Admission to Trading of its Shares on AIM, Expects to Take Place on 14 November 2023

Permira Advisers Ltd. completed the acquisition of Ergomed plc (AIM:ERGO) from Amati Global Investors Ltd. and others.

Ergomed Confirms Expected Scheme Timetable

Ergomed plc (AIM:ERGO) acquired Panacea Pharma Projects Limited from Stuart Colligon.

Permira Advisers Ltd. entered into a scheme of arrangement to acquire Ergomed plc (AIM:ERGO) from Amati Global Investors Ltd. and others for approximately £700 million.

Ergomed plc to Report Q2, 2023 Results on Sep 26, 2023

Now 20% undervalued after recent price drop

Is It Time To Consider Buying Ergomed plc (LON:ERGO)?

Ergomed plc Provides Earnings Forecast for the Full Year 2023

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Ergomed plc, Annual General Meeting, Jun 22, 2023

At UK£9.74, Is Ergomed plc (LON:ERGO) Worth Looking At Closely?

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

High number of new and inexperienced directors

Ergomed plc to Report Fiscal Year 2022 Results on Mar 21, 2023

High number of new and inexperienced directors

Ergomed plc Announces Board Changes, Effective 3 February 2023

Ergomed plc Announces Executive Changes

Ergomed plc Announces Directorate Changes

Ergomed Announces Two Senior Appointments to its Executive Team

Ergomed Strengthens Executive Management Team

Ergomed Strengthens Executive Management Team

Ergomed plc (LON:ERGO) Shares Could Be 21% Below Their Intrinsic Value Estimate

First half 2022 earnings released: EPS: UK£0.15 (vs UK£0.14 in 1H 2021)

Ergomed plc to Report First Half, 2022 Results on Sep 27, 2022

Investor sentiment improved over the past week

Should You Be Adding Ergomed (LON:ERGO) To Your Watchlist Today?

Why Ergomed plc (LON:ERGO) Could Be Worth Watching

Ergomed plc Appoints Anne Whitaker as Independent Non-Executive Director

Full year 2021 earnings: EPS misses analyst expectations

Ergomed plc, Annual General Meeting, Jun 10, 2022

Consensus EPS estimates increase by 11%

Consensus forecasts updated

Less than half of directors are independent

Now 21% undervalued

Calculating The Fair Value Of Ergomed plc (LON:ERGO)

Full year 2021 earnings: EPS misses analyst expectations

Does Ergomed (LON:ERGO) Deserve A Spot On Your Watchlist?

John Dawson, Cbe Joins the Board of Ergomed plc as Independent Non-Executive Director and Chair of the Audit Committee

Why Ergomed plc (LON:ERGO) Could Be Worth Watching

Ergomed plc to Report Fiscal Year 2021 Results on Mar 29, 2022

Pharmaust Limited Engages Ergomed Clinical Research Ltd to Commence Clinical Trials Testing the Anti-Viral Effects of Monepantel

Ergomed plc (AIM:ERGO) acquired Adamas Consulting Ltd. at an enterprise value of £24.2 million.

Ergomed plc Provides Revenue Guidance for the Year Ended 31 December 2021

Investor sentiment deteriorated over the past week

Calculating The Fair Value Of Ergomed plc (LON:ERGO)

Investor sentiment improved over the past week

I Ran A Stock Scan For Earnings Growth And Ergomed (LON:ERGO) Passed With Ease

First half 2021 earnings released: EPS UK£0.14 (vs UK£0.089 in 1H 2020)

Calculating The Intrinsic Value Of Ergomed plc (LON:ERGO)

Investor sentiment improved over the past week

If You Like EPS Growth Then Check Out Ergomed (LON:ERGO) Before It's Too Late

Getting In Cheap On Ergomed plc (LON:ERGO) Might Be Difficult

Ergomed plc (LON:ERGO) Shares Could Be 31% Above Their Intrinsic Value Estimate

Price target increased to UK£13.65

Non-Executive Director has left the company

Investor sentiment improved over the past week

Do Ergomed's (LON:ERGO) Earnings Warrant Your Attention?

Full year 2020 earnings released